Literature DB >> 20503236

Influence of polyhydramnios on perinatal outcome in pregestational diabetic pregnancies.

N Idris1, S F Wong, M Thomae, G Gardener, D H McIntyre.   

Abstract

OBJECTIVE: This study was carried out to evaluate the perinatal outcomes of pregnancy with pregestational diabetes mellitus complicated by polyhydramnios.
METHODS: This was a retrospective study of singleton pregnancies, with an antepartum diagnosis of polyhydramnios, seen at the maternal fetal medicine department of Mater Mothers' Hospital, a tertiary-level facility. All pregnancies in women with pregestational diabetes with a singleton pregnancy beyond 24 weeks of gestation, from 1996 to 2006, were reviewed (n = 314), and pregnancies complicated by polyhydramnios were identified (n = 59). Pregnancy outcomes of women whose pregnancy was complicated with polyhydramnios were compared to those without this complication.
RESULTS: The incidence of polyhydramnios in the study population was 18.8%. Women with polyhydramnios had increased hemoglobin A1c (HbA1c) levels throughout the pregnancy, and the difference was significant during the prepregnancy period and in the third trimester (P = 0.003 and P = 0.025, respectively). Significantly more mothers in the polyhydramnios group delivered preterm (54.2% vs. 33.3%, P = 0.004), the majority of which were iatrogenic preterm deliveries (44.1%). More pregnancies with polyhydramnios were delivered by Cesarean section (83.0% vs. 62%; P = 0.006), with the majority being performed electively in both groups (79.6% and 70.3%, respectively). Regardless, there were no significant differences in perinatal mortality rates, congenital abnormality rates, the incidences of low Apgar score, acidemia, hypoglycemia requiring intravenous therapy, phototherapy and ventilatory needs between the babies of the two groups.
CONCLUSION: Pregestational diabetic pregnancy with polyhydramnios is associated with poor diabetic control. Despite this, there is no significant increase in adverse perinatal outcome in these pregnancies, apart from a higher iatrogenic preterm birth rate. (c) 2010 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503236     DOI: 10.1002/uog.7676

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  6 in total

1.  The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetes.

Authors:  Saifur R Khan; Haneesha Mohan; Ying Liu; Battsetseg Batchuluun; Himaben Gohil; Dana Al Rijjal; Yousef Manialawy; Brian J Cox; Erica P Gunderson; Michael B Wheeler
Journal:  Diabetologia       Date:  2019-01-15       Impact factor: 10.122

2.  Polyhydramnios: Causes, Diagnosis and Therapy.

Authors:  A Hamza; D Herr; E F Solomayer; G Meyberg-Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-12       Impact factor: 2.915

3.  Study on the correlation and predictive value of serum pregnancy-associated plasma protein A, triglyceride and serum 25-hydroxyvitamin D levels with gestational diabetes mellitus.

Authors:  Zhuo Ren; Dong Zhe; Zhi Li; Xin-Ping Sun; Kai Yang; Li Lin
Journal:  World J Clin Cases       Date:  2020-03-06       Impact factor: 1.337

4.  Late-onset bloodstream infections in hospitalized term infants.

Authors:  Daniela Testoni; Madoka Hayashi; Michael Cohen-Wolkowiez; Daniel K Benjamin; Renato D Lopes; Reese H Clark; Daniel K Benjamin; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2014-09       Impact factor: 3.806

5.  Frequency of anomalies and hospital outcomes in infants with gastroschisis and omphalocele.

Authors:  Kristin M Corey; Christoph P Hornik; Matthew M Laughon; Kerstin McHutchison; Reese H Clark; P Brian Smith
Journal:  Early Hum Dev       Date:  2014-06-11       Impact factor: 2.699

Review 6.  Amniotic fluid as a vital sign for fetal wellbeing.

Authors:  Elizabeth A Dubil; Everett F Magann
Journal:  Australas J Ultrasound Med       Date:  2015-12-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.